CN103833747A - Salt of coptisine derivative - Google Patents
Salt of coptisine derivative Download PDFInfo
- Publication number
- CN103833747A CN103833747A CN201210485099.XA CN201210485099A CN103833747A CN 103833747 A CN103833747 A CN 103833747A CN 201210485099 A CN201210485099 A CN 201210485099A CN 103833747 A CN103833747 A CN 103833747A
- Authority
- CN
- China
- Prior art keywords
- coptisine
- compound
- pharmaceutically acceptable
- salt
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to coptisine, a coptisine derivative, and particularly relates to coptisine fumarate or a pharmaceutically acceptable solvate of the coptisine derivative and application of the coptisine fumarate and the pharmaceutically acceptable solvate in preparation of a methicillin-resistant staphylococcus aureus drug.
Description
Invention field
The present invention relates to pharmaceutical chemistry field, particularly, the present invention relates to coptisine organic acid salt and pharmacy application thereof.
Background technology
For now, although the medicine of methicillin-resistant staphylococcus aureus resistance is existing a variety of, existing these medicines easily cause many and heavy untoward reaction, and the result for the treatment of of existing medicine is still not ideal enough.The active compound that some have methicillin-resistant staphylococcus aureus resistance has been described in the patent specification that Chinese invention patent Granted publication number is CN 100586433C.
Summary of the invention
The invention discloses some new compound, the preparation method of these compounds, the pharmacy application of the pharmaceutical composition that contains these compounds and these compounds and composition.
These compounds have shown good water-soluble stability and solid form stability.Some compound of these compounds shows special good stability.These compounds are compared with corresponding free alkali, and it has very high solvability in water.
These compounds are compared with corresponding free alkali and are shown that in surprise the activity of its methicillin-resistant staphylococcus aureus resistance is higher because of synergy between the two.
Surprising and the significant stability of these compounds, water-soluble, anti-microbial activity are effectively preparation and a large amount of advantages that provide that use.
Therefore, the invention provides a kind of formula III compound:
｛（Ⅰ）H｝+Ⅱ
ˉ;
Wherein the chemical structure of I is as follows:
Wherein the chemical structure of II is as follows:
And/or pharmaceutically acceptable solvate, wherein:
II
--represent counter ion.
Suitable counter ion II
--the ion being provided by pharmaceutically acceptable organic acid is provided.
The preferred acceptable organic acid of medicine comprises cholic acid, Chenodiol, ursodesoxycholic acid, Deoxycholic Acid, tartrate, toxilic acid, fumaric acid, particularly fumaric acid.
Preferred counter ion are fumarate ions.
Formula III compound is salt.
Suitable pharmaceutically acceptable solvate is hydrate.
In addition, the present invention also provides the preparation method of formula III and/or pharmaceutically acceptable solvate.This method comprises formula I compound:
With counter ion II defined above
--source reaction, after this if necessary, then prepares its pharmaceutically acceptable solvate.
Suitable counter ion II
--source is pharmaceutically acceptable organic acid.
The preferred acceptable organic acid of medicine comprises cholic acid, Chenodiol, ursodesoxycholic acid, Deoxycholic Acid, tartrate, toxilic acid, fumaric acid, particularly fumaric acid.
Preferred source of counter ions is fumaric acid.
Formula I compound and counter ion II
--reaction between source is normally carried out under conventional salt-forming condition, for example, in solvent, be generally C1---C4 alkanol solvent as ethanol, can provide under the arbitrary temp that generates required suitable speed, conventionally at the temperature of for example solvent refluxing of temperature raising, be conveniently molar weight approximately to wait but preferably by slightly excessive counter ion II
--in the situation in source by formula I compound and counter ion II
--source is mixed then crystallization and is gone out required product (III).
The pharmaceutically acceptable solvate of formula III compound can be prepared by conventional chemical process.
Formula I compound can be prepared by the method for describing in the patent specification of CN100586433C according to Chinese invention patent Granted publication number.
Suitable source of counter ions is knownly can easily obtain through commercial sources, for example fumaric acid, or can prepare required source of counter ions according to known method.
The stability of the compounds of this invention can be measured with conventional quantitative analysis method; The stability of for example solid chemical compound can be measured with the stability test of accelerating, for example dsc (DSC), and thermo-gravimetric analysis (TGA) is tested with the thermoisopleth in intensification.This test comprises room temperature storage test.(in wherein during known under temperature and humidity control condition storage test compound).The quantitative analysis of test compound is before storage period, in storage period or after storage period.With respect to the stability of suitable reference standard determination test compound.
As mentioned above, compound of the present invention is compared with corresponding free alkali, and it has significantly high solvability in water.The ordinary method of measuring like this stability of the compounds of this invention in the aqueous solution be included in known temperature condition and known during in be settled out the degree of parent free alkali in the aqueous solution of mensuration by test compound, we find that formula III compound demonstrates good aqueous stability.Particularly II wherein
--the formula III compound of the fumaric acid radical representing is stable especially in the aqueous solution.II wherein that more surprised is
--the formula III compound of the fumaric acid radical representing is abnormal stablizing in the aqueous solution.
Described test compound quantitative analysis test can ordinary method, conventionally uses chromatography, and for example high pressure lipuid chromatography (HPLC) is carried out.
As mentioned above, compound of the present invention has practical therapeutic activity.
Therefore, the invention provides formula III compound and/or the pharmaceutically acceptable solvate as therapeutic active substance.
Like this, the invention provides formula III compound and/or the pharmaceutically acceptable solvate as methicillin-resistant staphylococcus aureus resistance.
Formula III compound and/or pharmaceutically acceptable solvate can himself form be used, and the form that preferably also can contain the pharmaceutical composition of pharmaceutically acceptable carrier is used.
Therefore, the present invention also provides a kind of pharmaceutical composition that contains formula III compound and/or pharmaceutically acceptable solvate and pharmaceutically acceptable carrier.
Term used herein " pharmaceutically acceptable " comprises compound, composition and the component to people and animal doctor's use, and for example, term " pharmaceutically acceptable salt " comprises the upper acceptable salt of animal doctor.
Suitable pharmaceutical composition is the composition of unit dosage, for example oral liquid, tablet, capsule, injection liquid, sprays.
Optimum pharmaceutical composition is oral liquid, sprays.
According to the convention on conventional medicine, carrier can comprise thinner, weighting agent, disintegrating agent, wetting agent, lubricant, tinting material, seasonings or other conventional additives.
Optimum composition is to be configured to unit dosage.
Conventionally, activeconstituents can aforementioned pharmaceutical compositions form be used.
The present invention also provides a kind of contain formula III compound and/or the application of pharmaceutically acceptable solvate on the medicine of producing methicillin-resistant staphylococcus aureus resistance.
Provide embodiments of the invention below for further illustrating and describe in more detail the present invention.
Embodiment 1
Coptisine fumarate
Compound coptisine 3.20 grams (0.01mol) and fumaric acid 1.17 grams (0.01mol) are dissolved in 90 milliliters of the ethanol of boiling.This hot solution is through diatomite filtration, and then Slow cooling under mild stirring leaves standstill a few hours in the temperature environment of 0-5 ℃, separate out coptisine fumarate crystal, leach coptisine fumarate crystal, with washing with alcohol dry under 50 ℃ of vacuum conditions, obtain 4.35 grams of products.
Embodiment 2
Coptisine fumarate
1.17 grams of 3.20 grams of compound coptisine fumarates and fumaric acid are stirred to solid in 90 milliliters of ethanol refluxing all to be dissolved.Add gac, this hot solution, through diatomite filtration, is cooled to room temperature in stirring.In the temperature environment of 0-5 ℃, leave standstill a few hours, separate out coptisine fumarate crystal, leach coptisine fumarate crystal, with washing with alcohol dry under 50 ℃ of vacuum conditions, obtain 4.33 grams of products.
The present invention can summarize with other the specific form without prejudice to spirit of the present invention or principal character.Therefore,, no matter from which point, above-mentioned embodiment of the present invention all can only think explanation of the present invention can not limit the present invention.
Claims (2)
1. coptisine (I) fumaric acid (II) salt (III);
2. the compound of claim 1 is in the application of preparing in methicillin-resistant staphylococcus aureus resistance medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210485099.XA CN103833747A (en) | 2012-11-26 | 2012-11-26 | Salt of coptisine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210485099.XA CN103833747A (en) | 2012-11-26 | 2012-11-26 | Salt of coptisine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103833747A true CN103833747A (en) | 2014-06-04 |
Family
ID=50797681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210485099.XA Pending CN103833747A (en) | 2012-11-26 | 2012-11-26 | Salt of coptisine derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103833747A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110041326A (en) * | 2018-01-15 | 2019-07-23 | 中国医学科学院药物研究所 | Berberine hydrochloride and fumaric acid eutectic object and preparation method and its composition and purposes |
-
2012
- 2012-11-26 CN CN201210485099.XA patent/CN103833747A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110041326A (en) * | 2018-01-15 | 2019-07-23 | 中国医学科学院药物研究所 | Berberine hydrochloride and fumaric acid eutectic object and preparation method and its composition and purposes |
| CN110041326B (en) * | 2018-01-15 | 2022-04-15 | 中国医学科学院药物研究所 | Eutectic compound of berberine hydrochloride and fumaric acid, preparation method, composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103833757A (en) | Salt of methoxy-canthin-6-tone derivative | |
| CN103626773A (en) | Salt of vasicine derivative | |
| CN103833747A (en) | Salt of coptisine derivative | |
| CN103833748A (en) | Salt of thalicarpine urbaini derivative | |
| CN103772475A (en) | Conimine derivative salts | |
| CN103833758A (en) | Salt of hydroxyl canthin-6-one derivative | |
| CN103772383A (en) | Salts of evodiamine derivatives | |
| CN103910677A (en) | Salt of corydine derivative | |
| CN103864688A (en) | Salt of oxodehydrocaaverine derivative | |
| CN103864809A (en) | Salt of oxocrebanine derivative | |
| CN103864806A (en) | Salts of crebanine derivative | |
| CN103833746A (en) | Salt of stylopine derivative | |
| CN103833749A (en) | Salt of apocavidine derivative | |
| CN103833750A (en) | Salt of dehydroapocavidine derivative | |
| CN103864807A (en) | Salts of dioxo-dehydrocrebanine derivative | |
| CN103864805A (en) | Salts of dehydrocrebanine derivative | |
| CN103864808A (en) | Salts of (-)sukhodianine derivative | |
| CN103910731A (en) | Salt of oxysophorcarpine derivative | |
| CN103910733A (en) | Salt of oxymatrine derivative | |
| CN103910732A (en) | Salt of dophoridine derivative | |
| CN103772474A (en) | Salts of conessine derivative | |
| CN103772470A (en) | Salts of conessine derivative | |
| CN103910729A (en) | Salt of matrine derivative | |
| CN103910724A (en) | Salt of picrasma quassioides alkaloid derivative | |
| CN103910730A (en) | Salt of sophocarpine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |